Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders;Valoración de la mutación V617F del gen JAK2 en síndromes mieloproliferativos crónicos con cromosoma Filadelfia negativo

Medicina Clinica

Volumn 127, Issue 16, 2006, Pages 601-604

  Remacha, Ángel F ^a   Puget, Guiomar ^b   Nomdedéu, Josep F ^a   Estivill, Camino ^a   Sardà, M Pilar ^a   Canals, Carme ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

BFU E; Essential thrombocytemia; JAK2; Myelofibrosis; Polycythemia vera

Indexed keywords

JANUS KINASE 2;

ALLELE; ARTICLE; BONE MARROW CELL; BURST FORMING UNIT E; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA DETERMINATION; ERYTHROID CELL; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 33845436783     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13094416     Document Type: Article

References (26)

1. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol. 2005;23:6285-95.
2. Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 2005;105:22-30.
3. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-8.
4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-8.
5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-90.
6. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-61.
7. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-97.
8. Cazzola M, Skoda R. Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. Haematologica. 2005;90:871-4.
9. Cazzola M, Passamonti F. Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. Haematologica. 2006;91:159-61.
10. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-5.
11. Goerttler PS, Steimle C, Marz E, Johansson PL, Andreasson B, Griesshammer M, et al. The Jak2 V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood. 2005;106:2862-4.
12. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005;106:2920-1.
13. Steensma DP. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both «atypical» myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-9.
14. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO classification. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
15. Bolumar F, Delgado F. Diseño de investigaciones en ciencias de la salud. Diseño para el estudio de pruebas diagnósticas y factores pronósticos. Barcelona: Signo; 1999.
16. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005;131:208-13.
17. Campbell PJ, Green AR. Management of polycythemia vera and essential thrombocythemia. Hematology (Am Soc Hematol Educ Program). 2005;59:201-8.
18. Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol. 2005;131:166-71.
19. Staerk J, Kallin A, Demoulin JB, Vainchenker W, Constantinescu SN. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem. 2005;280:41893-9.
20. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al; United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945-53.
21. Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology (Am Soc Hematol Educ Program). 2005;195-200.
22. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, et al; General Haematology Task Force of the British Committee for Standards in Haematology. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130:174-95.
23. Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med. 2003;139:470-5.
24. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost. 1997;23:411-8.
25. Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol. 2001;68:115-21.
26. Arellano-Rodrigo E, Álvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91:169-75.